BackMonte Rosa Therapeutics Overview
Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Target Price

Where could GLUE trade next? Consensus target price: $31.

Get informed when a big investor buys or sells

+ Follow

Share Price

$13.84

Average Target Price

$31.00124% upside

5 analysts in the last 4 months

High: $40 | Low: $25

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Guggenheim$28102.3% upsideOpen
2026-08-03WedbushRobert Driscoll$2795.1% upsideOpen
2026-07-31Jefferies$2580.6% upsideOpen
2026-07-27Jefferies$40189% upsideOpen
2026-06-30Guggenheim$35152.9% upsideOpen
2026-01-14Piper Sandler$37167.3% upsideOpen
2026-01-07Jefferies$31124% upsideOpen
2026-01-07Wedbush$37167.3% upsideOpen
2025-12-17JefferiesKelly Shi$2259% upsideOpen
2025-12-16Wells Fargo$2259% upsideOpen

Monte Rosa Therapeutics (GLUE) FAQ

The latest target price for GLUE is $31. Investors often review this figure alongside Monte Rosa Therapeutics's historical trend and sector peers before judging valuation or financial health.

Monte Rosa Therapeutics trades near $13.84 while the consensus target sits at $31 (124.0% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting GLUE's target price ($31), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Monte Rosa Therapeutics's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.